ACRP CP CERTIFICATION EXAM 2025 NEWEST ACTUAL EXAM
COMPLETE 300 QUESTIONS WITH DETAILED
VERIFIED ANSWERS (100% CORRECT ANSWERS) / ALREADY GRADED
A+
What are expected or possible consequences of over-estimation of recruitment
potential? - ANSWER- The trial will overrun its projected timeline
- The recruitment period will be prolonged and more sites may be needed
- The study will not have sufficient data within the required timeframe and will be
stopped because of lack of budget
What should be the first consideration when conducting a clinical trial? -
ANSWERSubject welfare
When is the investigator allowed to deviate from the protocol? - ANSWERWhen there is
an immediate hazard to a patient.
If the investigator wanted to deviate from the protocol for an immediate hazard to a
patient, according to ICH E6 guidelines who would they need to report the deviation and
rationale to, if appropriate? - ANSWER- The Sponsor
- IRB/IEC
- Regulatory Authorities
Which conditions should be fulfilled when enrolling a subject into your trial? - ANSWER-
Subject meets all inclusion criteria
- Subject has given written informed consent
You've been delegated to handle the storage and inventory of IP. The study drug must
be stored below 25C/77F. On a summer Monday morning you discover that the
temperature recording machine in the storage room has failed so you doin't know what
the temperature has been over the weekend. You check the current temperature; it's
24C/75F. What should you do? - ANSWER- Contact the Sponsor, explain what
happened and ask for instructions
- Set up a site staff meeting to conduct a root cause analysis
A protocol amendment was issued for a trial. Your site received IRB approval for the
amendment and wants to implement the increase in PO dose for your trial subjects as
identified in the amendment trial subjects. As delegated consenting duties you must re-
consent trial subjects before being able to administer the adjusted dose. You decide to
only re-consent trial subjects who are still taking the IP and not from the subjects woh
already completed their drug intake period. Is this allowed according the E6 Guideline
,for GCP? - ANSWERNo, these subjects are still enrolled in the trial and therefore need
to be updated on any changes to the protocol.
A trial subject informs you she no longer wants to participant in the trial. What should
your course of action be? - ANSWERYou ask if the patient wishes to share the reason
why she wants to leave the trial. If not, you exclude the subject from the trial
immediately.
A patient cannot recall the name of the heart condition medication he took a few years
ago. This is important information for deciding whether the patient may be enrolled in a
clinical trial (IC/EC). What's your best course of action? - ANSWERYou attempt to
retrieve the patients medical history by contacting previous caregivers and you wait for
additional information before enrollment.
Who has ultimate trial responsibility for each subject? - ANSWERThe principle
investigator.
A trial subject suffers from severe repeat headaches. Should this adverse event be
reported to the IRB? - ANSWERNo
What statements are true concerning an adverse drug reaction? - ANSWER- All
noxious and unintended responses to a medicinal product related to any dose should be
considered as an ADR
- An ADR suggests a relationship to trail medication
- All ADRs must be documented
What Adverse Events (AEs) are Serious Adverse Events (SAEs)? - ANSWER- Any AE
that results in death
- Any AE that results in inpatient hospitalization
- Any AE that is a congenital anomaly
During a study visit a patient tells the investigator that she visited an emergency room
and received intensive treatment for allergic bronchospasm. Since the patient was in the
emergency room for only three hours, the investigator did not assess the event as
serious. Is this a correct assessment? - ANSWERNo, this would be a medically
important event and should be considered serious
What data points minimally need to be reported by the site when reporting an SAE, so
that the sponsor can process the event? - ANSWERIdentification of event, product, and
trial subject
During a visit with investigator, a subject reported feeling heart palpitations for a brief
period of time during the previous evening. The heart palpitations resolved without
reoccurrence. The investigator considered these symptoms to be unrelated to study
drug. The next day, the subject told a fellow student that he felt tired and was planning
on taking a nap. Later, the subject was found dead. A preliminary report from the
, medical examiner indicated the subject died of pulmonary embolism. What should your
next course of action be? - ANSWER- Record these events in case report form
- Immediately notify sponsor about serious adverse events
When asked by a regulatory body why they received SAE related information on
12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason
being they received the trial related SAE information from the investigator in 12/2013. Is
the sponsor correct in only holding the investigator accountable for their late reporting? -
ANSWERNo, the sponsor should support the conduct QC activities with the sites to help
them ensure timely SAE reporting.
A trial subject in a cardiology trial is admitted to hospital with heart attack. The
investigator considers this event possibly related to the study drug even though this is
not listed in the IB as a potential adverse reaction. What would the investigator report
this event to the sponsor as? - ANSWERAn unexpected, serious adverse event
A 22y/o male was entered into a clinical study for treatment of schizophrenia The study
drug was administered orally, BID. One week later, the subject visited the investigator
complaining of sever sore throat. The IB lists this as an occurrence reported by 1% of
subjects receiving drug. How should this severe throat be classified? - ANSWER- An
adverse event
- An adverse drug reaction
In regards to AE and ADR reporting, what statements are true? - ANSWER- All ADRs
are AEs but not all AEs are ADRs
- Worsening in pre-existing medical conditions is an AE
-Preplanned hospitalization is usually not an SAE
What determines the causality of an adverse event? - ANSWERThe investigator
Which term best describes the cyclical process that involves the Plan, Do, Check, Act
activities? - ANSWERQuality improvement
Which term best describes an independent assessment of completed work to ensure it
will meet applicable quality standards? - ANSWERQuality assurance
Which term best describes the activities done to ensure quality output? -
ANSWERQuality control
Which term requires structure and a definition of acceptable standards of performance?
- ANSWERQuality planning
Which is represented in ALCOA-C? - ANSWERAttributable
What does CAPA stand for? - ANSWERCorrective and Preventive Action
COMPLETE 300 QUESTIONS WITH DETAILED
VERIFIED ANSWERS (100% CORRECT ANSWERS) / ALREADY GRADED
A+
What are expected or possible consequences of over-estimation of recruitment
potential? - ANSWER- The trial will overrun its projected timeline
- The recruitment period will be prolonged and more sites may be needed
- The study will not have sufficient data within the required timeframe and will be
stopped because of lack of budget
What should be the first consideration when conducting a clinical trial? -
ANSWERSubject welfare
When is the investigator allowed to deviate from the protocol? - ANSWERWhen there is
an immediate hazard to a patient.
If the investigator wanted to deviate from the protocol for an immediate hazard to a
patient, according to ICH E6 guidelines who would they need to report the deviation and
rationale to, if appropriate? - ANSWER- The Sponsor
- IRB/IEC
- Regulatory Authorities
Which conditions should be fulfilled when enrolling a subject into your trial? - ANSWER-
Subject meets all inclusion criteria
- Subject has given written informed consent
You've been delegated to handle the storage and inventory of IP. The study drug must
be stored below 25C/77F. On a summer Monday morning you discover that the
temperature recording machine in the storage room has failed so you doin't know what
the temperature has been over the weekend. You check the current temperature; it's
24C/75F. What should you do? - ANSWER- Contact the Sponsor, explain what
happened and ask for instructions
- Set up a site staff meeting to conduct a root cause analysis
A protocol amendment was issued for a trial. Your site received IRB approval for the
amendment and wants to implement the increase in PO dose for your trial subjects as
identified in the amendment trial subjects. As delegated consenting duties you must re-
consent trial subjects before being able to administer the adjusted dose. You decide to
only re-consent trial subjects who are still taking the IP and not from the subjects woh
already completed their drug intake period. Is this allowed according the E6 Guideline
,for GCP? - ANSWERNo, these subjects are still enrolled in the trial and therefore need
to be updated on any changes to the protocol.
A trial subject informs you she no longer wants to participant in the trial. What should
your course of action be? - ANSWERYou ask if the patient wishes to share the reason
why she wants to leave the trial. If not, you exclude the subject from the trial
immediately.
A patient cannot recall the name of the heart condition medication he took a few years
ago. This is important information for deciding whether the patient may be enrolled in a
clinical trial (IC/EC). What's your best course of action? - ANSWERYou attempt to
retrieve the patients medical history by contacting previous caregivers and you wait for
additional information before enrollment.
Who has ultimate trial responsibility for each subject? - ANSWERThe principle
investigator.
A trial subject suffers from severe repeat headaches. Should this adverse event be
reported to the IRB? - ANSWERNo
What statements are true concerning an adverse drug reaction? - ANSWER- All
noxious and unintended responses to a medicinal product related to any dose should be
considered as an ADR
- An ADR suggests a relationship to trail medication
- All ADRs must be documented
What Adverse Events (AEs) are Serious Adverse Events (SAEs)? - ANSWER- Any AE
that results in death
- Any AE that results in inpatient hospitalization
- Any AE that is a congenital anomaly
During a study visit a patient tells the investigator that she visited an emergency room
and received intensive treatment for allergic bronchospasm. Since the patient was in the
emergency room for only three hours, the investigator did not assess the event as
serious. Is this a correct assessment? - ANSWERNo, this would be a medically
important event and should be considered serious
What data points minimally need to be reported by the site when reporting an SAE, so
that the sponsor can process the event? - ANSWERIdentification of event, product, and
trial subject
During a visit with investigator, a subject reported feeling heart palpitations for a brief
period of time during the previous evening. The heart palpitations resolved without
reoccurrence. The investigator considered these symptoms to be unrelated to study
drug. The next day, the subject told a fellow student that he felt tired and was planning
on taking a nap. Later, the subject was found dead. A preliminary report from the
, medical examiner indicated the subject died of pulmonary embolism. What should your
next course of action be? - ANSWER- Record these events in case report form
- Immediately notify sponsor about serious adverse events
When asked by a regulatory body why they received SAE related information on
12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason
being they received the trial related SAE information from the investigator in 12/2013. Is
the sponsor correct in only holding the investigator accountable for their late reporting? -
ANSWERNo, the sponsor should support the conduct QC activities with the sites to help
them ensure timely SAE reporting.
A trial subject in a cardiology trial is admitted to hospital with heart attack. The
investigator considers this event possibly related to the study drug even though this is
not listed in the IB as a potential adverse reaction. What would the investigator report
this event to the sponsor as? - ANSWERAn unexpected, serious adverse event
A 22y/o male was entered into a clinical study for treatment of schizophrenia The study
drug was administered orally, BID. One week later, the subject visited the investigator
complaining of sever sore throat. The IB lists this as an occurrence reported by 1% of
subjects receiving drug. How should this severe throat be classified? - ANSWER- An
adverse event
- An adverse drug reaction
In regards to AE and ADR reporting, what statements are true? - ANSWER- All ADRs
are AEs but not all AEs are ADRs
- Worsening in pre-existing medical conditions is an AE
-Preplanned hospitalization is usually not an SAE
What determines the causality of an adverse event? - ANSWERThe investigator
Which term best describes the cyclical process that involves the Plan, Do, Check, Act
activities? - ANSWERQuality improvement
Which term best describes an independent assessment of completed work to ensure it
will meet applicable quality standards? - ANSWERQuality assurance
Which term best describes the activities done to ensure quality output? -
ANSWERQuality control
Which term requires structure and a definition of acceptable standards of performance?
- ANSWERQuality planning
Which is represented in ALCOA-C? - ANSWERAttributable
What does CAPA stand for? - ANSWERCorrective and Preventive Action
